| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Nuclear Medicine Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, and Division of Nuclear Medicine, Stanford University School of Medicine, Stanford, California
The annual incidence of primary intracranial tumors is 7 to 19 cases per 100,000 people. The general approach to the treatment of brain neoplasms is surgical resection of solitary lesions or limited disease, followed by radiation therapy with or without chemotherapy. Multiple metastatic lesions are usually treated with whole-brain radiation. Radiation injury occurs in 5% to 37% of cases and can be difficult to differentiate from residual or recurrent malignancy by MRI. PET has been used to differentiate radiation injury from malignancy on the basis of differences in glucose uptake. Recent studies have reported the sensitivity and specificity of PET to be 81% to 86% and 40% to 94%, respectively. This article reviews the classification of primary brain tumors, the histologic changes associated with radiation injury, and the diagnostic and prognostic information provided by PET.
Key Words: PET • FDG • glioma • radiation injury • radiation necrosis
Received May 24, 2000; revision accepted Jul. 13, 2000.
For correspondence or reprints contact: George M. Segall, MD, Nuclear Medicine Service 115, VA Palo Alto Health Care System, 3801 Miranda Ave., Palo Alto, CA 94304.
*NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ACTIVITY THROUGH THE SNM WEB SITE (http://www.snm.org) UNTIL MAY 2001.
This article has been cited by other articles:
|
|
 |
|
  A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology Neuro-oncol, January 1, 2008; 10(3): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Chen Clinical Applications of PET in Brain Tumors J. Nucl. Med., September 1, 2007; 48(9): 1468 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Wyss, N. Spaeth, G. Biollaz, J. Pahnke, P. Alessi, E. Trachsel, V. Treyer, B. Weber, D. Neri, and A. Buck Uptake of 18F-Fluorocholine, 18F-FET, and 18F-FDG in C6 Gliomas and Correlation with 131I-SIP(L19), a Marker of Angiogenesis J. Nucl. Med., April 1, 2007; 48(4): 608 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ceyssens, K. Van Laere, T. de Groot, J. Goffin, G. Bormans, and L. Mortelmans [11C]Methionine PET, Histopathology, and Survival in Primary Brain Tumors and Recurrence AJNR Am. J. Neuroradiol., August 1, 2006; 27(7): 1432 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Asao, Y. Korogi, M. Kitajima, T. Hirai, Y. Baba, K. Makino, M. Kochi, S. Morishita, and Y. Yamashita Diffusion-Weighted Imaging of Radiation-Induced Brain Injury for Differentiation from Tumor Recurrence AJNR Am. J. Neuroradiol., June 1, 2005; 26(6): 1455 - 1460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-Y. Guo Is Current Imaging Good Enough to Differentiate Radiation-Induced Brain Injury from Tumor Recurrence? AJNR Am. J. Neuroradiol., June 1, 2005; 26(6): 1305 - 1305. [Full Text] [PDF]
|
|
|
|
|
|
M. Henze, A. Mohammed, H. P. Schlemmer, K. K. Herfarth, S. Hoffner, S. Haufe, W. Mier, M. Eisenhut, J. Debus, and U. Haberkorn PET and SPECT for Detection of Tumor Progression in Irradiated Low-Grade Astrocytoma: A Receiver-Operating-Characteristic Analysis J. Nucl. Med., April 1, 2004; 45(4): 579 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Hein, C. J. Eskey, J. F. Dunn, and E. B. Hug Diffusion-Weighted Imaging in the Follow-up of Treated High-Grade Gliomas: Tumor Recurrence versus Radiation Injury AJNR Am. J. Neuroradiol., February 1, 2004; 25(2): 201 - 209. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
